Lymphangioleiomyomatosis: what do we know and what are we looking for? - Wikidata - awgldk - TriplyDB

Lymphangioleiomyomatosis: what do we know and what are we looking for?

Lymphangioleiomyomatosis: what do we know and what are we looking for?

http://www.wikidata.org/entity/Q36067383

about

Birt-Hogg-Dube syndrome: clinicopathological features of the lung Tuberous sclerosis complex: perioperative considerations.Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM).MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literature Lymphangioleiomyomatosis: current and future.Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.The lymphatic vasculature in disease.Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis.In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

P2860

Q24606257-74AEBE1E-607D-4378-ADC6-9C9D869DFACE Q33737529-7040988A-2F0D-4DBD-B9F9-C14E39623B9A Q34429336-16C49187-DDF1-444A-ABE4-3DBADC0A90B7 Q34652936-901CA0F8-ABC2-4AA8-9ADD-5628B5183328 Q35758056-057ACA13-95A8-4C59-A675-8486A4F2C269 Q36542254-9FC8DDFD-CDEF-4C8A-9B20-540F866EDC68 Q37173102-608E4B9D-1322-484A-AF82-109294D3C7A5 Q37953774-4D832D37-DE11-4BA6-B1EB-C33FDAA25A35 Q38414596-05BC9FCE-EA0E-4E4B-8CAC-201E5761431C Q39279796-7CD5520D-455C-4FA0-9748-C41FBC84AECD Q40330232-D59E9FF2-5020-47D6-9321-06A8749C2E0F Q40740177-C9130BDC-206C-42BD-ACD4-9072D89CA69B Q42645301-86BE230E-F5DF-414D-9DAE-DB0C07F7E1B0 Q46117088-8B8044E2-B65F-4F19-9082-42E2FEC3EA72 Q59126578-C30B0E28-6279-4CE5-8F95-6BED4716B13E

P2860

Lymphangioleiomyomatosis: what do we know and what are we looking for?

http://www.wikidata.org/entity/Q36067383

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@ast

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@en

type

label

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@ast

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@en

prefLabel

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@ast

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@en

P1433

Q36067383-A2A34D53-8C6A-4237-9B28-5868FBA0CC1D

P1476

Q36067383-DFE63780-7E45-4F34-A8AD-2B18CDD62D26

P2093

Q36067383-162812F7-F300-406C-90E6-C1962EF0CAF2

Q36067383-B42CB093-7866-450E-BD4F-A7353C50D9CB

Q36067383-FFE2C046-2C5D-4DC0-9886-BD10ADF9207D

P2860

Q36067383-048613A7-1CCC-4400-847B-9B9C0C304572

Q36067383-084538AA-DC87-4206-96E3-8D91A18D47B6

Q36067383-0959CA86-FBBE-4E81-A277-A72C328D5698

Q36067383-0CDC3E60-73E3-401C-A01E-47A02C26ADAC

Q36067383-0CFE3689-B516-4208-B951-2F118073A4F5

Q36067383-0E160BB4-EEA0-45CF-A976-B417C54236C7

Q36067383-0FFB2716-A471-4DBD-9701-38C8E58B919A

Q36067383-12961424-0FB9-442D-8201-DFC8FA2B72DC

Q36067383-1903A4CA-B932-4241-AEE1-2895FF7C7B8B

Q36067383-1AAA027B-D3C9-4F7F-A876-1DF3364E1B12

P304

Q36067383-AC5C2FBA-BAD4-4901-A24F-50060AF8B687

P31

Q36067383-89EA7E96-989C-422F-AAE4-2D17CBF536F3

P356

Q36067383-27B3327E-40E8-425E-AF20-C4F45710B747

P433

Q36067383-4A726692-A70D-4369-8A9B-F83327657FE8

P478

Q36067383-56DE9230-C77F-4E68-9CF0-C93420E4A535

P577

Q36067383-BC8FF576-4492-4891-BA8D-E249F5718F29

P5875

Q36067383-ECE603DA-32C6-4AE5-98FE-FA6064613FBB

P698

Q36067383-F10B10F2-988E-45B7-BFCC-DF162F1DD483

P932

Q36067383-93F313D0-9FBE-4439-9A16-85C09E74A585

P356

09059180.00011010

P1433

European Respiratory Review

P1476

Lymphangioleiomyomatosis: what do we know and what are we looking for?

@en

P2093

J Moss

http://www.w3.org/2001/XMLSchema#string

O Torre

http://www.w3.org/2001/XMLSchema#string

S Harari

http://www.w3.org/2001/XMLSchema#string

P2860

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3

The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton

Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products

Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases

Mutation and cancer: statistical study of retinoblastoma

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

TSC2 mediates cellular energy response to control cell growth and survival

P304

34-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09059180.00011010

http://www.w3.org/2001/XMLSchema#string

P433

119

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50226989

http://www.w3.org/2001/XMLSchema#string

P698

21357890

http://www.w3.org/2001/XMLSchema#string

P932

3386525

http://www.w3.org/2001/XMLSchema#string